Skip to content
TrialScanner

NCT07923071

A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment

Phase 1Not yet recruitingSNDXLead

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Relapsed/Refractory (R/R) Hematologic Malignancies; Acute Leukemia; Refractory Leukemia; Relapsed Leukemia
Primary completion
Jan 2030Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07923071 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07923071: A Study to Assess the... | TrialScanner